Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Atara Biotherapeutics Inc

ATRA
Current price
0.68 USD +0.0016 USD (+0.24%)
Last closed 0.68 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 84 506 176 USD
Yield for 12 month -77.50 %
1Y
3Y
5Y
10Y
15Y
ATRA
21.11.2021 - 28.11.2021

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. Address: 2380 Conejo Spectrum Street, Thousand Oaks, CA, United States, 91320

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

4.2 USD

P/E ratio

Dividend Yield

Current Year

+8 573 000 USD

Last Year

+63 573 000 USD

Current Quarter

+4 252 000 USD

Last Quarter

+2 138 000 USD

Current Year

-313 000 USD

Last Year

+49 005 000 USD

Current Quarter

+1 092 000 USD

Last Quarter

-477 000 USD

Key Figures ATRA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -264 447 008 USD
Operating Margin TTM -1922.44 %
PE Ratio
Return On Assets TTM -62.11 %
PEG Ratio
Return On Equity TTM -2014.86 %
Wall Street Target Price 4.2 USD
Revenue TTM 8 573 000 USD
Book Value -0.93 USD
Revenue Per Share TTM 0.081 USD
Dividend Share
Quarterly Revenue Growth YOY 1345.7 %
Dividend Yield
Gross Profit TTM 63 573 000 USD
Earnings Share -2.61 USD
Diluted Eps TTM -2.61 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ATRA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ATRA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ATRA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 10.7692
Price Sales TTM 9.8572
Enterprise Value EBITDA -0.3471
Price Book MRQ 1.9674

Financials ATRA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ATRA

For 52 weeks

0.2 USD 3.08 USD
50 Day MA 0.76 USD
Shares Short Prior Month 11 027 778
200 Day MA 1.13 USD
Short Ratio 4.7
Shares Short 11 227 598
Short Percent 9.61 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

414.58 USD Microsoft Corporation +0.12 (+0.03%)
Detailed analytics

ETF funds


M

MDAXEX

208.70 CHF iShares MDAX UCITS ETF (DE) -11.84 (-4.92%)
Detailed analytics

Metals


Gold

2169.94 USD Gold -5.94 (-0.27%)
Detailed analytics